Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model

被引:41
作者
Klepser, ME
Ernst, EJ
Petzold, CR
Rhomberg, P
Doern, GV
机构
[1] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA
[2] Univ Iowa, Coll Med, Iowa City, IA 52242 USA
关键词
D O I
10.1128/AAC.45.3.673-678.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Several new quinolones that exhibit enhanced in vitro activity against Streptococcus pneumoniae have been developed. Using a dynamic in vitro model, we generated time-kill data for ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against three isolates of quinolone-susceptible S, pneumoniae, Three pharmacokinetic profiles were simulated for each of the study agents (0.1, 1, and 10 times the area under the concentration-time curve [AUC]), Target 24-h AUCs were based upon human pharmacokinetic data resulting from the maximal daily doses of each agent. Ciprofloxacin was the least active agent against all three isolates, With regimens that simulated the human 24-h AUC, ciprofloxacin resulted in an initial, modest decline in the numbers of CFU per milliliter; however, by 48 h the numbers of CFU per milliliter returned to or exceeded the starting inoculum, At the AUC, levofloxacin resulted in variable bacteriostatic and bactericidal activities against the isolates. The remaining agents yielded bactericidal (99.9% reduction) activity by 48 h with regimens that simulated the AUC. At 0.1 time the AUC ciprofloxacin and levofloxacin produced no inhibitory effect, grepafloxacin exhibited bacteriostatic activity, trovafloxacin had mixed static and cidal activities, and clinafloxacin and moxifloxacin caused significant reductions in the numbers of CFU per milliliter by 48 h, All six agents produced cidal activity at 10 times the AUC. In this dynamic in vitro model of infection, the quinolones demonstrated various degrees of activity against S, pneumoniae, The rank order of activity, with respect to bactericidal effect, was ciprofloxacin (least active) much less than levofloxacin < grepafloxacin, trovafloxacin < clinafloxacin and moxifloxacin (most active), The rank order of the agents with respect to the selection of resistance was ciprofloxacin (most likely) > grepafloxacin, moxifloxacin, and trovafloxacin > levofloxacin > clinafloxacin.
引用
收藏
页码:673 / 678
页数:6
相关论文
共 22 条
[1]   IN-VITRO ACTIVITIES OF 12 ORALLY-ADMINISTERED ANTIMICROBIAL AGENTS AGAINST 4 SPECIES OF BACTERIAL RESPIRATORY PATHOGENS FROM US-MEDICAL-CENTERS IN 1992 AND 1993 [J].
BARRY, AL ;
PFALLER, MA ;
FUCHS, PC ;
PACKER, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) :2419-2425
[2]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[3]   CIPROFLOXACIN IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC-BRONCHITIS [J].
DAVIES, BI ;
MAESEN, FPV ;
BAUR, C .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1986, 5 (02) :226-231
[4]   In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae [J].
Davies, TA ;
Pankuch, GA ;
Dewasse, BE ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1177-1182
[5]   Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America:: 1997 results from the SENTRY antimicrobial surveillance program [J].
Doern, GV ;
Pfaller, MA ;
Kugler, K ;
Freeman, J ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) :764-770
[6]   Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study [J].
Doern, GV ;
Brueggemann, A ;
Holley, HP ;
Rauch, AM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1208-1213
[7]   Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus [J].
Dong, YZ ;
Zhao, XL ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1756-1758
[8]   Primary targets of fluoroquinolones in Streptococcus pneumoniae [J].
Fukuda, H ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :410-412
[9]   SUPERINFECTION WITH STREPTOCOCCUS-PNEUMONIAE DURING THERAPY WITH CIPROFLOXACIN [J].
GORDON, JJ ;
KAUFFMAN, CA .
AMERICAN JOURNAL OF MEDICINE, 1990, 89 (03) :383-384
[10]   CIPROFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC-BRONCHITIS [J].
HOOGKAMPKORSTANJE, JAA ;
KLEIN, SJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 (03) :407-413